selegiline

Selegiline hydrochloride is a selective, reversible inhibitor of MAO-B (Ki = 0.091 μM) over MAO-A (Ki = 9.06 μM). Monoamine oxidase (MAO) inhibitors have utility in ameliorating a variety of neurological conditions, including depression.

Ciglitazone (ADD 3878) is a potent and selective PPARγ agonist (EC50: 3 μM) and oral hypoglycemic agent. Ciglitazone inhibits proliferation and differentiation of th17 cells, decreases insulin levels, vascular endothelial growth factor production and blood pressure, and induces cell cycle arrest in gastric cancer cells. Selegiline induces apoptosis in opossum kidney epithelial cells and activates nuclear translocation of p38 MAPK and apoptosis-inducing factor (AIF). Ciglitazone exhibits hypoglycaemic activity in animal models of obesity and hyperglycaemia.

2-PAT, analogous to Rasagiline and Selegiline, functions as a reversible MAO-A inhibitor, exhibiting an IC50 of 0.721 µM, and acts as an inactivator of MAO-B with an IC50 value of 14.6 µM. This compound shows promise for research in Parkinson's disease and depression.